AUTHORS
Xiangping Zong, Jin Zhou, MD2, Tao You, MD3, Qian Wang, MS4, Depei Wu Sr, MD5, Haiwen Huang, PhD6
AFFILIATIONS
1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
3 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
5 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
6 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
ABSTRACT
Background
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains associated with poor outcomes, particularly among patients with multiple prior therapies and high-risk clinical features. Tafasitamab combined with lenalidomide has demonstrated clinical activity in R/R DLBCL; however, the efficacy and safety of combining tafasitamab–lenalidomide with immunochemotherapy remain insufficiently characterized. This study evaluated the preliminary efficacy and safety of tafasitamab–lenalidomide combined with investigator-selected immunochemotherapy in patients with high-risk R/R DLBCL.
Methods
This interim analysis included patients enrolled in a prospective, single-center, open-label, single-arm phase II study. Patients with R/R DLBCL received tafasitamab–lenalidomide combined with investigator-selected immunochemotherapy, including R-GemOx-, R-DHAP-, MINE-, mini-CHOP-, and R-EPOCH-based regimens. Treatment selection was based on prior therapy, disease characteristics, and patient fitness.
Tafasitamab was administered intravenously at 12 mg/kg on days 1 and 4 according to the study protocol. Lenalidomide was administered orally at 25 mg on days 1–10 of each cycle, with dose interruption or reduction according to hematologic tolerance and blood counts.
Response was assessed after two cycles, primarily by PET/CT. The primary efficacy endpoints were overall response rate (ORR) and complete response/complete metabolic response (CR/CMR) rate. ORR was defined as CR/CMR plus partial response (PR). Patients without objective response and with early clinical treatment failure were categorized as non-responders (NR). Observed progression-free survival (PFS), overall survival (OS), and safety were secondary endpoints. Adverse events (AEs) were prospectively monitored and graded according to the maximum documented severity.
Results
Twelve patients were included. The median age was 62.5 years (range, 40–80). Eight patients (66.7%) were female, 8 (66.7%) had non-germinal center B-cell-like (non-GCB) disease, all patients had stage III/IV disease, and 10 (83.3%) had an International Prognostic Index (IPI) score ≥3, indicating a high-risk population. TAFA-LEN-based therapy was administered at a median treatment line of 2 (range, 1–4).
After two cycles, the ORR was 58.3% (7/12), including CR/CMR in 25.0% (3/12) and PR in 33.3% (4/12). Four patients (33.3%) experienced progressive disease, and one patient (8.3%) was classified as a non-responder due to absence of objective response and early treatment failure.
The median observed PFS was 3.0 months (range, 0.5–9.0). At a median follow-up of 3.8 months (range, 1.5–9.0), median OS was not reached; 2 patients had died and 10 patients (83.3%) remained alive at the data cutoff.
During follow-up, one responding patient subsequently underwent autologous stem-cell transplantation (ASCT), and another transplant-eligible patient was undergoing ASCT evaluation.
AEs were reported in 9 patients (75.0%). Neutropenia and thrombocytopenia were each reported in 8 patients (66.7%). Grade ≥3 hematologic AEs occurred in 6 patients (50.0%), including grade 4 hematologic AEs in 4 patients (33.3%). Cytomegalovirus positivity and elevated liver enzymes were each reported in one patient.
Conclusions
Tafasitamab–lenalidomide combined with immunochemotherapy demonstrated encouraging preliminary activity in this high-risk R/R DLBCL cohort, achieving an ORR of 58.3% and a CR/CMR rate of 25.0%. Hematologic toxicity was frequent, emphasizing the importance of close monitoring, individualized dose modification, and supportive care. Selected responding patients were able to proceed to subsequent consolidation treatment, including ASCT in one case. Larger studies with longer follow-up are required to further define response durability and survival outcomes.
DISCLOSURES
Xiangping Zong: No relevant conflicts of interest to declare.